3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
14
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma
10
Leukemia
10
Myelodysplastic Syndromes
9
Multiple Myeloma
9
Leukemia, Lymphocytic, Chronic, B-Cell
9
Congenital Abnormalities
9
Lymphoma, Follicular
8
Hodgkin Disease
8
Recurrence
7
Lymphoma, Non-Hodgkin
7
Lymphoma, Mantle-Cell
7
Lymphoma, Large-Cell, Immunoblastic
7
Lymphoma, Large B-Cell, Diffuse
7
Primary Myelofibrosis
6
Neoplasms, Plasma Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Burkitt Lymphoma
6
Blast Crisis
6
Myeloproliferative Disorders
5
Lymphoma, T-Cell, Cutaneous
5
Leukemia, Myeloid, Accelerated Phase
5
Dendritic Cell Sarcoma, Interdigitating
5
Polycythemia Vera
4
Anemia, Refractory, with Excess of Blasts
4
Waldenstrom Macroglobulinemia
3
Thrombocythemia, Essential
3
Interventions
fludarabine phosphate
1
fludarabine
1
Mesna
1
Cyclophosphamide
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase NA
×
Thalassemia
×
Busulfan
×
Clear all
NCT00578292
2020-05-01
THALLO
Baylor College of Medicine
Phase NA
Terminated
10 enrolled
15 charts